API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2024/02/12/2827863/0/en/G1-Therapeutics-to-Continue-Pivotal-Phase-3-Trial-of-Trilaciclib-in-Metastatic-Triple-Negative-Breast-Cancer-Following-Interim-Analysis-by-Independent-Data-Monitoring-Committee.html
https://www.globenewswire.com//news-release/2023/10/27/2768288/0/en/Real-World-Data-Indicate-That-Trilaciclib-Reduces-Hospitalizations-and-Myelosuppressive-Events-and-May-Improve-Survival-in-Patients-with-Extensive-Stage-Small-Cell-Lung-Cancer-ES-S.html
https://www.globenewswire.com//news-release/2023/10/18/2762334/0/en/G1-Therapeutics-COSELA-trilaciclib-Recommended-in-Updated-Small-Cell-Lung-Cancer-Guidelines-from-the-American-Society-of-Clinical-Oncology-ASCO.html
https://www.globenewswire.com/news-release/2023/07/31/2714895/0/en/New-Publication-Highlights-Real-World-Impact-of-Trilaciclib-on-Myelosuppressive-Events-in-Patients-with-Extensive-Stage-Small-Cell-Lung-Cancer-ES-SCLC.html
https://www.reuters.com/business/healthcare-pharmaceuticals/g1-therapeutics-discontinue-cancer-drug-trial-shares-plunge-40-2023-02-13/
https://www.prnewswire.com/news-releases/first-prescription-for-cosela-trilaciclib-issued-in-china-301743018.html
https://www.globenewswire.com/news-release/2023/01/09/2584970/0/en/G1-Therapeutics-Announces-Upcoming-2023-Readouts-from-its-Phase-2-and-Pivotal-Phase-3-Clinical-Trials-of-Trilaciclib.html
https://www.globenewswire.com/news-release/2022/11/02/2546265/0/en/Initial-Results-from-Phase-2-Trial-Demonstrate-Potential-of-Trilaciclib-to-Reduce-Adverse-Events-Related-to-an-Antibody-Drug-Conjugate-ADC.html
https://www.globenewswire.com/news-release/2022/10/10/2530822/0/en/G1-Therapeutics-Completes-Enrollment-in-Global-Multi-Center-Phase-3-Clinical-Trial-of-Trilaciclib-in-Patients-with-Metastatic-Triple-Negative-Breast-Cancer-TNBC.html
https://www.globenewswire.com/news-release/2022/06/13/2461057/0/en/G1-Therapeutics-Announces-Completion-of-Enrollment-in-Global-Multi-Center-Phase-3-Clinical-Trial-of-Trilaciclib-in-Patients-with-Metastatic-Colorectal-Cancer.html
https://www.globenewswire.com/news-release/2022/06/02/2455424/0/en/Data-Presented-at-ASCO-Demonstrate-Trilaciclib-Helps-Protect-Against-Severe-Neutropenia-Severe-Anemia-and-Severe-Thrombocytopenia-When-Given-to-Extensive-Stage-Small-Cell-Lung-Canc.html
https://www.prnewswire.com/news-releases/proprietary-sars-cov-2-3cl-inhibitor-rapidly-progressing-in-clinical-trials-market-approval-of-trilaciclib-expected-in-china-simcere-reveals-global-innovation-ambition-on-rd-day-301527579.html
https://www.globenewswire.com/news-release/2022/03/31/2414334/0/en/New-Real-World-Data-Show-Potential-of-Trilaciclib-to-Reduce-the-Substantial-Burden-of-Myelosuppression-in-Patients-with-Extensive-Stage-Small-Cell-Lung-Cancer-Treated-with-Chemothe.html
https://www.globenewswire.com/news-release/2021/12/16/2353400/0/en/G1-Therapeutics-Announces-Expansion-of-COSELA-Trilaciclib-Sales-Force.html
https://www.globenewswire.com/news-release/2021/11/12/2333433/0/en/Immune-Analysis-from-Phase-2-Triple-Negative-Breast-Cancer-Trial-Demonstrates-Trilaciclib-Enhanced-Patients-T-Cell-Immune-Function-When-Administered-Prior-to-Chemotherapy.html
https://www.globenewswire.com/news-release/2021/09/15/2297327/0/en/G1-Therapeutics-Announces-New-Supplemental-COSELA-Trilaciclib-Sales-Force.html
https://icer.org/news-insights/press-releases/icer-to-assess-novel-agents-to-prevent-chemotherapy-induced-neutropenia/
https://www.globenewswire.com/news-release/2021/03/02/2185061/0/en/G1-Therapeutics-and-Boehringer-Ingelheim-Announce-Commercial-Availability-of-COSELA-trilaciclib-the-Only-FDA-Approved-Multilineage-Myeloprotection-Therapy-to-Decrease-the-Incidence.html
https://www.biospace.com/article/releases/g1-therapeutics-to-present-data-on-trilaciclib-at-north-america-conference-on-lung-cancer-naclc-/
https://www.globenewswire.com/news-release/2020/05/13/2033083/0/en/G1-Therapeutics-to-Present-Data-Showing-Myelopreservation-Benefits-of-Trilaciclib-in-Patients-with-Small-Cell-Lung-Cancer-at-the-ASCO20-Virtual-Scientific-Program.html